Matrix metalloproteinase 2 genotype is associated with nonanastomotic biliary strictures after orthotopic liver transplantation
Article first published online: 1 FEB 2011
© 2011 John Wiley & Sons A/S
Volume 31, Issue 8, pages 1110–1117, September 2011
How to Cite
Ten Hove, W. R., Korkmaz, K. S., op den Dries, S., de Rooij, B.-J. F., van Hoek, B., Porte, R. J., van der Reijden, J. J., Coenraad, M. J., Dubbeld, J., Hommes, D. W. and Verspaget, H. W. (2011), Matrix metalloproteinase 2 genotype is associated with nonanastomotic biliary strictures after orthotopic liver transplantation. Liver International, 31: 1110–1117. doi: 10.1111/j.1478-3231.2011.02459.x
- Issue published online: 7 AUG 2011
- Article first published online: 1 FEB 2011
- Received 1 October 2010, Accepted 2 January 2011
- biliary strictures;
- gene polymorphisms;
- liver transplantation;
- matrix metalloproteinases
Background: Nonanastomotic biliary strictures (NAS) are a serious complication after orthotopic liver transplantation (OLT). Matrix metalloproteinases (MMPs) are involved in connective tissue remodelling in chronic liver disease and complications after OLT.
Aim: To evaluate the relationship between MMP-2 and MMP-9 gene polymorphisms and NAS.
Methods: MMP-2 (−1306 C/T) and MMP-9 (−1562 C/T) gene promoter polymorphisms were analysed in 314 recipient–donor combinations. Serum levels of these MMPs were determined in subgroups of patients as well. NAS were identified with various radiological imaging studies performed within 4 years after OLT and defined as any stricture, dilation or irregularity of the intra- or extrahepatic bile ducts of the liver graft followed by an intervention, after exclusion of hepatic artery thrombosis and anastomotic strictures.
Results: The average incidence of NAS was 15%. The major clinical risk factor for the development of NAS was PSC in the recipient. The presence of the MMP-2 CT genotype in donor and/or recipient was associated with a significantly higher incidence of NAS, up to 29% when both donor and recipient had the MMP-2 CT genotype (P=0.003). In the multivariate analyses, pre-OLT PSC (hazard ratio 2.1, P=0.02) and MMP-2 CT genotype (hazard ratio 3.5, P=0.003) were found to be independent risk factors for the development of NAS after OLT. No obvious association was found between NAS and the MMP-9 genotype and serum levels of the MMPs.
Conclusion: MMP-2 CT genotype of donor and recipient is an independent risk factor, in addition to PSC, for the development of NAS after OLT.